Sugi Predict

Sugi Predict / Compounds / SCHEMBL848335

SCHEMBL848335

SCHEMBL848335

CC(=O)c1ccc(Cl)cc1[N+](=O)[O-]

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 4/20 0.56
▸ CYP1A2 P05177 2/20 0.56
▸ CYP3A4 P08684 2/20 0.56
▸ CYP2C19 P33261 2/20 0.56
▸ FLT1 P17948 1/20 0.56
▸ FLT4 P35916 1/20 0.56
▸ KDR P35968 1/20 0.56
▸ POLB P06746 1/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ TSHR P16473 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ NPC1 O15118 2/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ ALDH1A1 P00352 1/20 0.50
▸ VCAM1 P19320 1/20 0.49
▸ HTT P42858 1/20 0.47
▸ USP7 Q93009 1/20 0.47
▸ USP47 Q96K76 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29758067 1.00 HPGD (0.56) HPGDCYP1A2CYP3A4CYP2C19FLT1
SCHEMBL339922 0.86 ALDH1A1 (0.57) POLBSMN1; SMN2TSHRMAPK1ALDH1A1
SCHEMBL11301098 0.85 HPGD (0.59) HPGDCYP1A2CYP3A4CYP2C19FLT1
SCHEMBL16042729 0.84 HPGD (0.51) HPGDCYP1A2CYP3A4CYP2C19FLT1
SCHEMBL535327 0.84 HPGD (0.58) HPGDCYP1A2CYP3A4CYP2C19FLT1
SCHEMBL2204732 0.84 HPGD (0.57) HPGDCYP1A2CYP3A4CYP2C19FLT1
SCHEMBL8631251 0.82 HPD (0.53) HPGDCYP1A2CYP3A4CYP2C19FLT1
SCHEMBL8489227 0.82 HPGD (0.57) HPGDCYP1A2CYP3A4CYP2C19FLT1
SCHEMBL6896167 0.82 HPGD (0.56) HPGDCYP1A2CYP3A4CYP2C19FLT1
SCHEMBL30176207 0.82 HPGD (0.56) HPGDCYP1A2CYP3A4CYP2C19FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111635358-B Preparation method of hydroxychloroquine 北京成宇化工有限公司 2022-06-03 — — CN claimed
CN-111635358-A Preparation method of hydroxychloroquine 北京成宇化工有限公司 2020-09-08 — — CN claimed
EP-4653053-A1 PPARG INVERSE AGONISTS AND USES THEREOF Flare Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
EP-4426434-B1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC (US) 2025-08-20 — — EP disclosed
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
US-20240166624-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-05-23 — — US disclosed
CN-117616012-A PPARG inverse agonists and uses thereof 弗拉雷治疗公司 2024-02-27 — — CN disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
EP-4301734-A1 PPARG INVERSE AGONISTS AND USES THEREOF Flare Therapeutics Inc. (US) 2024-01-10 — — EP disclosed
US-20070259877-A1 Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders GLAXO GROUP LIMITED 2007-11-08 — — US disclosed
WO-2007056170-A2 PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES BAYER HEALTHCARE AG (DE) 2007-05-18 — — WO disclosed
EP-1778679-A1 PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS GLAXO GROUP LIMITED (GB) 2007-05-02 — — EP disclosed
WO-2006010629-A1 PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS GLAXO GROUP LIMITED (GB) 2006-02-02 — — WO disclosed
WO-1994002145-A2 2-ARYL-4-QUINOLONES AS ANTITUMOR COMPOUNDS GENELABS TECHNOLOGIES, INC. (US) 1994-02-03 — — WO disclosed
US-4656267-A RENAL VASODILATORS, CARDIOVASCULAR AGENTS ORTHO PHARMACEUTICAL CORPORATION (US) 1987-04-07 — — US disclosed
US-4555571-A Substituted 2(1H)-quinazolinone-1-alkanoic acids and esters ORTHO PHARMACEUTICAL CORPORATION (US) 1985-11-26 — — US disclosed
EP-0138491-A2 Substituted 2(1H)-quinazolinone-1-alkanoic acids and esters ORTHO PHARMACEUTICAL CORPORATION (US) 1985-04-24 — — EP disclosed
US-4379929-A BACTERIOSTATS ELI LILLY AND COMPANY (US) 1983-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166624-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD HPGD 371/4885CYP1A2 434/4885CYP3A4 687/4885
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS HPGD 4385/4885CYP1A2 4341/4885CYP3A4 4449/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS HPGD 3845/4885CYP1A2 1845/4885CYP3A4 2066/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS HPGD 3845/4885CYP1A2 1845/4885CYP3A4 2066/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS HPGD 4095/4885CYP1A2 3408/4885CYP3A4 3708/4885
US-20070259877-A1 Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders GHSR, GHRHR, GIPR HPGD 672/4885CYP1A2 694/4885CYP3A4 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.